Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.ufba.br/handle/ri/13892
metadata.dc.type: | Artigo de Periódico |
Título : | Adjunctive benefits of systemic etoricoxib in non-surgical treatment of aggressive periodontitis: short-term evaluation |
Otros títulos : | Journal of Periodontology |
Autor : | Azoubel, Maria Cecília Fonsêca Sarmento, Viviane Almeida Lima, Virna Luci Cangussu Azoubel, Eduardo Bittencourt, Sandro Cunha, Fernando Q. Ribeiro, Ronaldo A. Brito, Gerly Anne de Castro |
metadata.dc.creator: | Azoubel, Maria Cecília Fonsêca Sarmento, Viviane Almeida Lima, Virna Luci Cangussu Azoubel, Eduardo Bittencourt, Sandro Cunha, Fernando Q. Ribeiro, Ronaldo A. Brito, Gerly Anne de Castro |
Resumen : | Background: This pilot study assessed the effect of short-duration treatment with etoricoxib as adjuvant therapy to scaling and root planing (SRP) on the clinical and radiographic parameters and prostaglandin E2 (PGE2) levels in aggressive periodontitis. Methods: Subjects were randomly allocated to test or control treatment (n = 10 in each group) and submitted to SRP and treatment with etoricoxib, 120 mg/day, or placebo for 7 days. Probing depth, clinical attachment level (CAL), gingival recession, visible plaque index, bleeding on probing, linear distance (LD) from the cemento-enamel junction to the alveolar crest, and analysis of the gray levels were recorded before and 1 month after the therapies. The prostaglandin E2 (PGE2) level in the gingival crevicular fluid (GCF) was measured by radioimmunoassay at the beginning of the study and 7 and 30 days after treatment. Results: No significant difference in the clinical parameters was observed between the groups at the end of the experimental period, although both groups presented significant improvement in all variables examined. There was a decrease in CAL from 5.54 ± 0.47 mm to 3.59 ± 0.53 mm in the test group and from 5.92 ± 1.10 mm to 3.69 ± 0.80 mm in the control group. A significant reduction in PGE2 was found after 7 days of treatment. LD differed between the groups. Conclusion: Etoricoxib did not promote additional improvement in the clinical parameters; however, it produced an initial reduction in the PGE2 levels in the GCF, which could be related to the discrete improvement in the bone condition. |
Palabras clave : | Anti-inflammatory agents Clinical trial Dental scaling toricoxib Periodontitis Root planing |
metadata.dc.publisher.country: | Brasil |
metadata.dc.rights: | Acesso Aberto |
URI : | http://repositorio.ufba.br/ri/handle/ri/13892 |
Fecha de publicación : | 2008 |
Aparece en las colecciones: | Artigo Publicado em Periódico (Faculdade de Odontologia) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
jop%2E2008%2E080019.pdf | 489,98 kB | Adobe PDF | Visualizar/Abrir |
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.